ArticleIn vivo (Athens, Greece)

Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab

Shogo Nakamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.